2022 Fiscal Year Final Research Report
Mechanism of hyperhomocysteinemia in chronic renal failure and its involvement in the development of cardiovascular disease
| Project/Area Number |
20K07188
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 高ホモシステイン血症 / 腎不全 / 血管障害 / メチオニン / ホモシステイン / 代謝フラックス / 安定同位体 / GC-MS |
|---|
| Outline of Final Research Achievements |
Renal failure is a frequent complication of cardiovascular disease. As decreased renal function increased plasma concentration of homocysteine, a rick factor for cardiovascular disease, hyperhomocysteinemia is thought to play in the development and progression of cardiovascular disease in patients with renal failure. To elucidate changes in the methionine-homocysteine metabolic system when hyperhomocysteinemia is associated with renal failure, we performed metabolic flux analysis in a 5/6-nephrectomized rats with hyperhomocysteinemia, which was bred on a homocystine-added diet.The findings indicate that the metabolic turnover of the transsulfuration pathway is enhanced so that homocysteine is irreversibly removed.
|
| Free Research Field |
病態生理学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、腎不全と高ホモシステイン血症を合併したモデルを作出し、その体内動態を検討した。両者が合併すると、ホモシステインを非可逆的に除去する方向にメチオニンーホモシステイン代謝系が変化している知見が得られた。末期腎不全患者は心血管疾患を合併することが知られているが、バイオマーカーとしてホモシステインの血漿濃度を定期的に測定してリスク評価し、高ホモシステイン血症を合併しないような対策が重要と考えられた。
|
